LONDON, UK: RTW Venture Fund Limited’s portfolio company Ventyx Biosciences Inc. announced pricing of an upsized $151.5 million initial public offering (IPO) and admission to trade on Nasdaq Global Market under ticker “VTYX”. Ventyx is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with…